

SAOSS (Rev. 1/94) Subnocena in a Civil Case

# Issued by the UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT	DISTRICT OF		NEW YORK
In re: Pharmaceutical Average Wholesale Pr V.	ice Lit.	AMENDED SUBPOENA IN	A CIVIL CASE
TO: Sudler & Hennessey, 230 Park Avenu York, NY 10003-1566	ue South, 8th Fl., New	Case Number:   M	USDC District of
☐ YOU ARE COMMANDED to appear in testify in the above case.	n the United States Distric	et court at the place, o	late, and time specified below to
PLACE OF TESTIMONY			COURTROOM
			DATE AND TIME
☐ YOU ARE COMMANDED to appear at in the above case.	the place, date, and time	specified below to te	L stify at the taking of a deposition
PLACE OF DEPOSITION			DATE AND TIME
YOU ARE COMMANDED to produce a place, date, and time specified below (li SEE ATTACHED RIDER	and permit inspection and st documents or objects):	copying of the follo	wing documents or objects at the
PLACE Goodkind Labaton Rudof 100 Park Ave., New Yor	f & Sucharow,	LLP .	DATE AND TIME
☐ YOU ARE COMMANDED to permit in	aspection of the following	g premises at the date	8/16/04 9:00 a.m. and time specified below.
FREMISES	***************************************		DATE AND TIME
Any organization not a party to this suit that directors, or managing agents, or other persons the matters on which the person will testify. Fee	who consent to testify on its deral Rules of Civil Proceds	behalf, and may set for ore, 30(b)(6).	designate one or more officers, orth, for each person designated,
ISSUING OFFICER'S SIGNATURE AND TITLE (INDICATION OF INDICATION OF INDIC	_	TIFF OR DEFENDANT)	DATE
ISSUING OFFICER'S NAME, ADDRESS AND PHONE N	(Placinetiff)		7-26-04
Anthony J. Sievert, The Wexler Firm LLP, C Tel: 312-346-2222		ite 2000, Chicago, IL	. 60602
(See Rule 4	5, Federal Rules of Civil Procedure, Pr	ns C & D on next page)	

<sup>&</sup>lt;sup>1</sup> If action is pending in district other than district of issuance, state district under case number.

AO88 (Rev. 1/94) Subpoens in a Civil	Case		07/26 205:43 P
	P	ROOF OF SERVICE	- ANDL
	DATE	PLACE	
SERVED			
SERVED ON (PRINT NAME)		MANNER OF SERVICE	
SERVED BY (PRINT NAME)		TITLE	
	DECI	ARATION OF SERVER	
I declare under penalty of in the Proof of Service is tru	perjury under the laws ae and correct.	of the United States of America that the foreg	going information contained
Executed on	DATE	SIGNATURE OF SERVER	
	271.12	SIGNATURE OF SERVER	
		ADDRESS OF SERVER	
		<del></del>	

### Rule 45, Federal Rules of Civil Procedure, Parts C & D:

### (c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS,

- (1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction which may include, but is not limited to, lost earnings and reasonable attorney's fee.
- (2) (A) A person commanded to produce and permit inspection and copying of designated books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.
- (B) Subject to paragraph (d) (2) of this rule, a person commanded to produce and permit inspection and copying may, within 14 days after service of subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to inspection or copying of any or all of the designated materials or of the premises. If objection is made, the party serving the subpoena shall not be entitled to inspect and copy materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production. Such an order to comply production shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection and copying commanded.
- (3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it
  - (i) fails to allow reasonable time for compliance,
- (ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that, subject to the provisions of clause (c) (3) (B) (iii) of this rule, such a person may in order to attend

trial be commanded to travel from any such place within the state in which the trial is held, or

- (iii) requires disclosure of privileged or other protected matter and no exception or waiver applies, or
  - (iv) subjects a person to undue burden.
  - (B) If a subpocna
- (i) requires disclosure of a trade secret or other confidential research, development, or commercial information, or
- (ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or
- (iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject to or affected by the subpoena, quash or modify the subpoena, or, if the party in who behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

- A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.
- (2) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the numedemanding party to contest the claim.



TO: Sudler & Hennessey, 1633 Broadway, New York, NY 10019.

### EXHIBIT A

- 1. "AstraZeneca" shall mean Zeneca, Inc., AstraZeneca US, AstraZeneca Pharmaceuticals, LP, AstraZeneca, PLC, AstraZeneca Pharmaceuticals, LP (collectively "AstraZeneca") and its predecessors, subsidiaries, parent organizations, branches, departments, agents, divisions and/or affiliates, including but not limited to, any other organization in which it has management or controlling interest(s), together with all present and former directors, officers, employees, agents and representatives of AstraZeneca, and any person acting or purporting to act on its behalf.
- 2. "You" means Sudler & Hennessey, as well as its predecessors and successors, and its employees, officers, directors, agents, attorneys, affiliates or any person acting on your behalf.
- 3. The term "document" includes, without limitation, the originals of all writings of every kind, including but not limited to letters, telegrams, memoranda, reports, studies, legal pleadings, speeches, calendars, diary entries, travel records and vouchers, promotional materials, pamphlets, handwritten notes, drafts, lists, directives, reports, tabulations, minutes and records of meetings, and telephone records, which are now or formerly were in the actual or constructive possession and control of you, your officers, directors, employees, attorneys or other agents. The term "document" further includes data processing and computer printouts, tapes, disks, and data stored in computers or data processing equipment, together with programs and program documentation necessary to retrieve, read and utilize such data, and all other mechanical or electronic means of storing or recording data, as well as tape, film or cassette sound and/or visual recordings, and reproductions or film impressions of any of the aforementioned writings. The term "document" also includes copies of all documents which are not identical duplicates of the originals, and copies

of documents if the originals of documents are not in the possession, custody or control of you, your officers, directors, employees, attorneys or other agents. Alteration of documents includes, without limitation, any modification, censorship, redaction, addition to or changing, which obscures, removes, amends, changes or obliterates any part of the original language, information, or meaning.

- 4. The term "communication" shall mean any act, action, oral speech, written correspondence, contact, expression of words, thoughts, or ideas or transmission of exchange of data or other information to another person, whether orally, person-to-person, in a group, by telephone, letter, personal delivery, telex, facsimile, or any other process, electric, electronic or otherwise. All such communications in writing shall include, without limitation, printed, typed, handwritten, electronic, or other readable documents.
- 5. Unless otherwise specifically stated herein, the period covered by each of these requests extends from January 1, 1991 to the date of your response to these discovery requests.
- 6. "Relating to" or "related to" shall include describing, discussing, reflecting, constituting, evidencing, referring to, pertaining to, concerning, involving, memorializing, dealing with and bearing on (whether legally, factually, or otherwise).
- 7. The connectives "and/or" are to be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope, and are not to be interpreted in such a manner as to exclude any information within the scope of the document request.
- 8. All documents produced should be produced in the order in which you maintain them in the ordinary course of your business.

- 07/26/04 205:43 PM ET SO
- 9. You should produce the original of each document requested together with all non-identical copies and drafts of that document. If the original of a document cannot be located, a copy should be produced in lieu thereof, and should be eligible and bound or stapled in the same manner as the original.
- 10. Documents not otherwise responsive to these requests should be produced if such documents mention, discuss, refer to or explain one or more documents that are called for by these document requests or if such documents are attached to documents called for by these document requests and constitute routing slips, transmittal memoranda or letters, comments, evaluations or similar materials.
  - 11. Documents attached to each other should not be separated.
- 12. "AstraZeneca drugs" means Atacand, Nexium, Entocort, Accolate, Armidex, Casodex, Diprivan, Nolvadex, Prilosec, Pulmicort, Rhinocort, Seroquel, Toprol, Zestril, Zomig, and Zoladex and any other drugs manufactured or marketed by AstraZeneca.

- 1. All contracts or other documents relating to any agreement by you to perform services for or to be retained by AstraZeneca.
- All documents reflecting any detail of the work you performed on behalf of or related to AstraZeneca, including but not limited to advertising services performed with respect to any AstraZeneca drug.
- All documents that concern, refer or relate to any strategic consultancy and communications support, or continuing educational programming, that you performed on behalf of AstraZeneca.



- 4. All billing records, diaries, calendars and invoices, relating or referring to work performed by you on behalf of or related to AstraZeneca.
- 5. All documents prepared by you or within your control or possession concerning, mentioning or relating to AstraZeneca.
- 6. All notes prepared, drafted or otherwise used by you relating to AstraZeneca and the services you provided to AstraZeneca.
- All current and historical organizational charts for you and all of your departments.
- 8. All documents that concern, refer or relate to promotional services, marketing, advertising or public relations work that you performed on behalf of AstraZeneca,
- 9. All advertising materials, including drafts, prepared by you that concern, refer or relate to any AstraZeneca drug.
- 10. All documents used in the preparation of any advertising materials that concern, refer or relate to any AstraZeneca drug.
- 11. All studies, analyses, reports or other documents comparing or contrasting in any way (including but not limited to pricing) Zoladex to any other pharmaceutical product, including Lupron.
- 12. All studies, analyses, reports or other documents comparing or contrasting in any way (including but not limited to pricing) any AstraZeneca drug to any competing pharmaceutical product.
  - 13. All documents that concern, refer or relate to prices for any AstraZeneca drug.



- 14. All documents concerning, relating to or referring to your policy for the generation, location, retention and destruction of your documents or files, including hard copy and in electronic form.
- 15. All documents sufficient to identify the databases maintained by you and the information they contain.

AO 88 (Rev. 1/94) Subpoena in a Civil Case



# Issued by the UNITED STATES DISTRICT COURT

### EASTERN DISTRICT OF MISSOURI

In re: Pharmaceutical Average Wholesale Price Lit.

٧.

# SUBPUENA IN A CIVIL CASE

Master File No. 01-cv-12257 CASE NUMBER: MDL 1456

Pending in the USDC Dist. of 3 Massachusett
Judge Patti B. Saris

TO: The Benfield Group, 20 Allen Ave., Suite 345, St. Louis, MO 63119

YOU ARE COMMANDED to appear in the United States District Court at the place, date, testify in the above case.	and time specified below to
PLACE OF TESTIMONY	COURTROOM
	DATE AND TIME
YOU ARE COMMANDED to appear at the place, date, and time specified below to testify at the above case.	t the taking of a deposition in
PLACE OF DEPOSITION	DATE AND TIME
YOU ARE COMMANDED to produce and permit inspection and copying of the following of place, date, and time specified below (list documents or objects):  SEE ATTACHED RIDER	documents or objects at the
PLACE Favre Law Office, LLC, 121 East Main Street., Belleville, IL 62220	DATE AND TIME 8/16/04 9:00 a.m.
YOU ARE COMMANDED to permit inspection of the following premises at the date and	I time specified below.
PREMISES	DATE AND TIME
Any organization not a party to this suit that is subpoenaed for the taking of a deposition s officers, directors, or managing agents, or other persons who consent to testify on its behalf, a person designated, the matters on which the person will testify. Federal Rules of Civil Pro	and may set forth, for each
ISSUING OFFICER SIGNATURE AND TITLE (INDICATE IF ATTORNEY FOR PLAINTIFF OR DEFENDANT)  (R lown+i ff)	7-26-04
ISSUING OFFICER'S NAME. ADDRESS AND PHONE NUMBER Anthony J. Sivert, The Wexler Firm LLT, One N. LaSalle St., Suite 2000, Chicago 312/346-2222	, IL 60601

AO 88 (Rev. 1/94) Subpoena in a Civil Case		05:43 PM ET
		MOL HO
	PROOF OF SERVICE	<del></del>
DATE	PLACE	
SERVED		
GERVED		
SERVED ON (PRINT NAME)	MANNER OF SERVICE	
SERVED BY (PRINT NAMED	TITLE	
	DECLARATION OF SERVER	
l declare under penalty of periury un	nder the laws of the United States of America that the foreg	coing information
contained in the Proof of Service is true a	nd correct.	,
Executed on		***************************************
DATE	SIGNATURE OF SERVER	
	ADDRESS OF SERVER	

#### Rule 45, Federal Rules of Civil Procedure, Parts C & D-

### (c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.

- (1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction which may include, but is not limited to, lost earnings and reasonable attorney's fee.
- (2) (A) A person commanded to produce and permit inspection and copying of designated books. papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.
- (B) Subject to paragraph (d) (2) of this rule, a person commanded to produce and permit inspection and copying may, within 14 days after service of subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to inspection or copying of any or all of the designated materials or of the premises, if objection is made, the party serving the subpoena shall not be entitled to inspect and copy materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production. Such an order to compel production shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection and copying commanded.
- (3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it  $% \left\{ 1\right\} =\left\{ 1\right\}$
- (i) fails to allow reasonable time for compliance:
  (ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in

person. except that, subject to the provisions of clause (c) (3) (B) (iii) of this rule, such a person may in order to attend trial be commanded to travel from any such place within the state in which the trial is held, or (iii) requires disclosure of privileged or other protected matter and no exception or waiver applies, or (iv) subjects a person to undue burden.

07/26/04

### (B) If a subpoena

(i) requires disclosure of a trade secret or other confidential research, development, or commercial information, or (II) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party or

(iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject to or affected by the subpoena, quash or modify the subpoena, or, if the party in whose behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

- (1) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.
- (2) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.



TO: The Benfield Group, 20 Allen Avenue, Suite 345, St. Louis, Missouri 63119

### EXHIBIT A

- 1. "AstraZeneca" shall mean Zeneca, Inc., AstraZeneca US, AstraZeneca Pharmaceuticals, LP, AstraZeneca, PLC, AstraZeneca Pharmaceuticals, LP (collectively "AstraZeneca") and its predecessors, subsidiaries, parent organizations, branches, departments, agents, divisions and/or affiliates, including but not limited to, any other organization in which it has management or controlling interest(s), together with all present and former directors, officers, employees, agents and representatives of AstraZeneca, and any person acting or purporting to act on its behalf.
- 2. "You" means the Benfield Group, as well as its predecessors, and its employees, officers, directors, agents, attorneys, affiliates or any person acting on your behalf.
- 3. The term "document" includes, without limitation, the originals of all writings of every kind, including but not limited to letters, telegrams, memoranda, reports, studies, legal pleadings, speeches, calendars, diary entries, travel records and vouchers, promotional materials, pamphlets, handwritten notes, drafts, lists, directives, reports, tabulations, minutes and records of meetings, and telephone records, which are now or formerly were in the actual or constructive possession and control of you, your officers, directors, employees, attorneys or other agents. The term "document" further includes data processing and computer printouts, tapes, disks, and data stored in computers or data processing equipment, together with programs and program documentation necessary to retrieve, read and utilize such data, and all other mechanical or electronic means of storing or recording data, as well as tape, film or cassette sound and/or visual recordings, and reproductions or film impressions of any of the aforementioned writings. The term "document" also includes copies of all documents which are not identical duplicates of the originals, and copies



of documents if the originals of documents are not in the possession, custody or control of you, your officers, directors, employees, attorneys or other agents. Alteration of documents includes, without limitation, any modification, censorship, redaction, addition to or changing, which obscures, removes, amends, changes or obliterates any part of the original language, information, or meaning.

- 4. The term "communication" shall mean any act, action, oral speech, written correspondence, contact, expression of words, thoughts, or ideas or transmission of exchange of data or other information to another person, whether orally, person-to-person, in a group, by telephone, letter, personal delivery, telex, facsimile, or any other process, electric, electronic or otherwise. All such communications in writing shall include, without limitation, printed, typed, handwritten, electronic, or other readable documents.
- 5. Unless otherwise specifically stated herein, the period covered by each of these requests extends from January 1, 1991 to the date of your response to these discovery requests.
- 6. "Relating to" or "related to" shall include describing, discussing, reflecting, constituting, evidencing, referring to, pertaining to, concerning, involving, memorializing, dealing with and bearing on (whether legally, factually, or otherwise).
- 7. The connectives "and/or" are to be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope, and are not to be interpreted in such a manner as to exclude any information within the scope of the document request.
- 8. All documents produced should be produced in the order in which you maintain them in the ordinary course of your business.

07/26/04

į

- 9. You should produce the original of each document requested together with all non-identical copies and drafts of that document. If the original of a document cannot be located, a copy should be produced in lieu thereof, and should be eligible and bound or stapled in the same manner as the original.
- 10. Documents not otherwise responsive to these requests should be produced if such documents mention, discuss, refer to or explain one or more documents that are called for by these document requests or if such documents are attached to documents called for by these document requests and constitute routing slips, transmittal memoranda or letters, comments, evaluations or similar materials.
  - 11. Documents attached to each other should not be separated.
- 12. "AstraZeneca drugs" means Atacand, Nexium, Entocort, Accolate, Armidex, Casodex, Diprivan, Nolvadex, Prilosec, Pulmicort, Rhinocort, Seroquel, Toprol, Zestril, Zomig, and Zoladex and any other drugs manufactured or marketed by AstraZeneca.

- All contracts or other documents relating to any agreement by you to perform services for or to be retained by AstraZeneca.
- 2. All documents reflecting any detail of the work you performed on behalf of or related to AstraZeneca, including but not limited to portfolio contracting analyses, market research, market testing, focus groups, data preparation, patient advocacy and education programs, continuing medical education programs, promotional services, advertising and public relations.
- 3. All records, diaries, calendars and invoices, relating to the work performed by you related to AstraZeneca.



- 4. All documents prepared by you or within your control or possession concerning, mentioning or relating to AstraZeneca.
- 5. All notes prepared, drafted or otherwise used by you relating to AstraZeneca and the services you provided to AstraZeneca.
- 6. All documents that concern, refer or relate to any pharmaceutical pricing strategy advice that you provided to AstraZeneca.
- 7. All studies, analyses, reports or other documents comparing or contrasting any AstraZeneca drug to any competing pharmaceutical product.
- 8. All documents that concern, refer or relate to prices for any AstraZeneca drug, including but not limited to documents that concern, refer or relate to average wholesale prices ("AWP"), return to practice ("RTP"), return on investment, spread or profit.
- All documents concerning, relating to or referring to your policy for the generation, location, retention and destruction of your documents or files, both in hard copy and electronic format.
  - 10. All current and historical organizational charts for all of your departments.
- 11. All documents sufficient to identify the databases maintained by you and the information they contain.

AO 88 (Rev. 1/94) Subpoena in a Civil Case - SDNY WEB 4/99



# Issued by the

UNITED STATES DISTRICT COURT			
Southern	DISTRICT OF	N	ew York
In Re: Average Wholesale Price Litigation		-	
		SUBPOENA IN	A CIVIL CASE
<b>V.</b>		Master File N CASE NUMBER: 1 MDL	io. 01-CV-12257
		Pending in th	e USDC Dist. of
		Massachusett Judge Patti E	l Sarie
TO:			
TO: Accenture, Ltd., New York City, 1345 Av	enue of the Americas, N	ew York, New York 101	05
YOU ARE COMMANDED to appear in the L in the above case.	Inited States District Cou	rt at the place, date, and	time specified below to testify
PLACE OF TESTIMONY			COURTROOM
			DATE AND TIME
	····	· · · · · · · · · · · · · · · · · · ·	
YOU ARE COMMANDED to appear at the the above case.	place, date, and time sp	ecified below to testify a	t the taking of a deposition in
PLACE OF DEPOSITION			DATE AND TIME
YOU ARE COMMANDED to produce and podate, and time specified below (list documents	ermit inspection and copy or objects):	ring of the following docu	ments or objects at the place,
SEE ATTACHED RIDER			
PLACE			In the same
Goodkind Labaton Rudoff & Sucharow, LLP 100 Park Avenue, New York, NY 10017	·		8/16/04 9:00 a.m.
YOU ARE COMMANDED to permit inspec	tion of the following prep	nises at the date and tim	ne specified helow
PREMISES			DATE AND TIME
	<del></del>		<u> </u>
Any organization not a party to this suit the officers, directors, or managing agents, or other designated, the matters on which the person was a suit of the person was a	persons who consent to	testify on its behalf, and	may set forth, for each person
ISSUING OFFICER SIGNATURE AND TITLE (INDICATE IF ATTORNEY FOR	PLAINTIFF OR DEFENDANT)		DATE
Un any	Pitural 93	<del>(1)</del>	7-26-04
ISSUING OFFICER'S NAME, ADDRESS AND PHONE NUMBER Anthony J. Slevert, The Wexler Firm, One N. LaSalle St., 312/345-2222			
(See Rule 4	15, Federal Rules of Civil Procedure, Par	is C & D on Reverse)	······································

<sup>&</sup>lt;sup>1</sup> If action is pending in district other than district of issuance, state district under case number.

AO 88 (Rev. 1/94) Subpoena in a Civil Case - SDNY WEB	/99 07/26/\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	/99 (95:43 PM)
	PROOF OF SERVICE
DATE	PLACE
SERVED	
SERVED ON (PRINT NAME)	MANNER OF SERVICE
SERVED BY (PRINT NAME)	TITLE
	DECLARATION OF SERVER
I declare under penalty of perjury under in the Proof of Service is true and correct.	he laws of the United States of America that the foregoing information contained
Executed on	SIGNATURE OF SERVER
	ADDRESS OF SERVER

### Rule 45, Federal Rules of Civil Procedure, Parts C & D:

### (c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.

- (1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction which may include, but is not limited to, lost earnings and reasonable attorney's fee.
- (2) (A) A person commanded to produce and permit inspection and copying of designated books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.
- (B) Subject to paragraph (d)(2) of this rule, a person commanded to produce and permit inspection and copying may, within 14 days after service of subpoena or before the time specified for compiliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to inspection or copying of any or all of the designated materials or of the premises. If objection is made, the party serving the subpoena shall not be entitled to inspect and copy materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production. Such an order to compel production shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection and copying commanded.
- (3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it
  - falls to allow reasonable time for compliance,
- (ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that,

subject to the provisions of clause (c)(3)(B)(iii) of this rule, such a person may in order to attend trial be commanded to travel from any such place within the state in which the trial is held, or

- (iii) requires disclosure of privileged or other protected matter and no exception or waiver applies, or
  - (iv) subjects a person to undue burden.
  - (B) If a subpoena

(f) requires disclosure of a trade secret or other confidential research, development, or commercial information, or

 (ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or

(iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject to or affected by the subpoena, quash or modify the subpoena, or, if the party in whose behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

- (1) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.
- (2) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.



TO: Accenture, Ltd., New York City, 1345 Avenue of the Americas, New York, New York 10105

### EXHIBIT A

- 1. "AstraZeneca" shall mean Zeneca, Inc., AstraZeneca US, AstraZeneca Pharmaceuticals, LP, AstraZeneca, PLC, AstraZeneca Pharmaceuticals, LP (collectively "AstraZeneca") and its predecessors, subsidiaries, parent organizations, branches, departments, agents, divisions and/or affiliates, including but not limited to, any other organization in which it has management or controlling interest(s), together with all present and former directors, officers, employees, agents and representatives of AstraZeneca, and any person acting or purporting to act on its behalf.
- 2. "You" means Accenture, Ltd., as well as its predecessors, and its employees, officers, directors, agents, attorneys, affiliates or any person acting on your behalf.
- 3. The term "document" includes, without limitation, the originals of all writings of every kind, including but not limited to letters, telegrams, memoranda, reports, studies, legal pleadings, speeches, calendars, diary entries, travel records and vouchers, promotional materials, pamphlets, handwritten notes, drafts, lists, directives, reports, tabulations, minutes and records of meetings, and telephone records, which are now or formerly were in the actual or constructive possession and control of you, your officers, directors, employees, attorneys or other agents. The term "document" further includes data processing and computer printouts, tapes, disks, and data stored in computers or data processing equipment, together with programs and program documentation necessary to retrieve, read and utilize such data, and all other mechanical or electronic means of storing or recording data, as well as tape, film or cassette sound and/or visual recordings, and reproductions or film impressions of any of the aforementioned writings. The term "document" also includes copies of all documents which are not identical duplicates of the originals, and copies



of documents if the originals of documents are not in the possession, custody or control of you, your officers, directors, employees, attorneys or other agents. Alteration of documents includes, without limitation, any modification, censorship, reduction, addition to or changing, which obscures, removes, amends, changes or obliterates any part of the original language, information, or meaning.

- 4. The term "communication" shall mean any act, action, oral speech, written correspondence, contact, expression of words, thoughts, or ideas or transmission of exchange of data or other information to another person, whether orally, person-to-person, in a group, by telephone, letter, personal delivery, telex, facsimile, or any other process, electric, electronic or otherwise. All such communications in writing shall include, without limitation, printed, typed, handwritten, electronic, or other readable documents.
- 5. Unless otherwise specifically stated herein, the period covered by each of these requests extends from January 1, 1991 to the date of your response to these discovery requests.
- 6. "Relating to" or "related to" shall include describing, discussing, reflecting, constituting, evidencing, referring to, pertaining to, concerning, involving, memorializing, dealing with and bearing on (whether legally, factually, or otherwise).
- 7. The connectives "and/or" are to be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope, and are not to be interpreted in such a manner as to exclude any information within the scope of the document request.
- 8. All documents produced should be produced in the order in which you maintain them in the ordinary course of your business.



- 9. You should produce the original of each document requested together with all non-identical copies and drafts of that document. If the original of a document cannot be located, a copy should be produced in lieu thereof, and should be eligible and bound or stapled in the same manner as the original.
- 10. Documents not otherwise responsive to these requests should be produced if such documents mention, discuss, refer to or explain one or more documents that are called for by these document requests or if such documents are attached to documents called for by these document requests and constitute routing slips, transmittal memoranda or letters, comments, evaluations or similar materials.
  - 11. Documents attached to each other should not be separated.
- 12. "AstraZeneca drugs" means Atacand, Nexium, Entocort, Accolate, Armidex, Casodex, Diprivan, Nolvadex, Prilosec, Pulmicort, Rhinocort, Seroquel, Toprol, Zestril, Zomig, and Zoladex and any other drugs manufactured or marketed by AstraZeneca.

- 1. All contracts or other documents relating to any agreement by you to perform services for or to be retained by AstraZeneca.
- 2. All documents reflecting any detail of the work you performed on behalf of or related to AstraZeneca, including but not limited to portfolio contracting analyses, market research, market testing, focus groups, systems integration and business integration, enterprise resource planning, customer relationship management and electronic services, data preparation, patient advocacy and education programs, continuing medical education programs, promotional services, advertising and public relations.

- 3. All records, diaries, calendars and invoices, relating to the work performed by you related to AstraZeneca.
- 4. All documents prepared by you or within your control or possession concerning, mentioning or relating to AstraZeneca.
- 5. All notes prepared, drafted or otherwise used by you relating to AstraZeneca and the services you provided to AstraZeneca.
- 6. All documents that concern, refer or relate to any pharmaceutical pricing strategy advice that you provided to AstraZeneca.
- All studies, analyses, reports or other documents comparing or contrasting any
   AstraZeneca drug to any competing pharmaceutical product.
- 8. All documents that concern, refer or relate to prices for any AstraZeneca drug, including but not limited to documents that concern, refer or relate to average wholesale prices ("AWP"), return to practice ("RTP"), return on investment, spread or profit.
- 9. All documents concerning, relating to or referring to your policy for the generation, location, retention and destruction of your documents or files, both in hard copy and electronic format.
  - 10. All current and historical organizational charts for all of your departments.
- 11. All documents sufficient to identify the databases maintained by you and the information they contain.

AO 88 (Rev. 1/94) Subpoena in a Civil Case - SDNY WEB 4/99



# Issued by the UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT	DISTRICT OF	NEW YORK
In re: Pharmaceutical Industry Average Who Litigation	olesale Price	SUBPOENA IN A CIVIL CASE
<b>V.</b>		Master File No. 01-CV-12257 CASE NUMBER: MDL NO. 1456
		Pending in the USDC District of Massachusetts Judge Patti B. Saris
TO: RUDER FINN, INC. c/o PETER FINN,	301 EAST 57th STREET,	NEW YORK, NY 10022
YOU ARE COMMANDED to appear in the in the above case.	United States District Cou	t at the place, date, and time specified below to testify
PLACE OF TESTIMONY		COURTROOM
		DATE AND TIME
YOU ARE COMMANDED to appear at the the above case.	e place, date, and time sp	ecified below to testify at the taking of a deposition in
PLACE OF DEPOSITION		DATE AND TIME
YOU ARE COMMANDED to produce and date, and time specified below (list document SEE ATTACHED RIDER	permit inspection and copy ts or objects):	ing of the following documents or objects at the place,
PLACE Goodkind Labaton Rudoff	& Sücharow I.I.D	DATE AND TIME
100 Park Ave., New York,	, NY 10017	8/16/04 9:00 a.m
YOU ARE COMMANDED to permit inspe	ction of the following prem	ises at the date and time specified below.
PREMISES		DATE AND TIME
Any organization not a party to this suit to officers, directors, or managing agents, or other designated, the matters on which the person	er persons who consent to t	taking of a deposition shall designate one or more estify on its behalf, and may set forth, for each person of Civil Procedure, 30(b)(6).
ISSUING OFFICER SIGNATURE AND TITLE (INDICATE IF ATTORNEY FO	OR PLAINTIFF OR DEFENDANT)	DATE
ISSING DESIGNED MALE APPRECIATION OF THE PARTY OF THE PAR	S CRbindy	F) 7-260-04
ISSUING OFFICER'S NAME, ADDRESS WO PHONE NUMBER Anthony J. Slevert, The Wexler Firm LLP, One N. LaSall Tel: 312/346-2222	le Street, Suite 2000, Chicago, iL	60602

<sup>(</sup>See Rule 45, Federal Rules of Civil Procedure, Parts C & D on Reverse)

<sup>&</sup>lt;sup>1</sup> If action is pending in district other than district of issuance, state district under case number.

AO 88 (Rev. 1/94) Subpoena in a Civil Case - SDNY WE	B 4/99	07/26/0 305:43 PM
		05:43 PM
	PROOF OF SERVICE	
DATE	PLACE	
SERVED		
SERVED ON (PRINT NAME)	MANNER OF SERVICE	·
SERVED BY (PRINT NAME)	TITLE	
	DECLARATION OF SERVER	
I declare under penalty of perjury under in the Proof of Service is true and correct.	er the laws of the United States of America that the foregoing information of	contained
Executed on	SIGNATURE OF SERVER	<del></del>
	ADDRESS OF SERVER	·
		<del></del>

### Rule 45, Federal Rules of Civil Procedure, Parts C & D:

### (c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.

- (1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate senction which may include, but is not limited to, lost earnings and reasonable attorney's fee.
- (2) (A) A person commanded to produce and permit inspection and copying of designated books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or triat.
- (B) Subject to paragraph (d)(2) of this rule, a person commanded to produce and permit inspection and copying may, within 14 days after service of subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to inspection or copying of any or all of the designated materials or of the premises. If objection is made, the party serving the subpoena shall not be entitled to inspect and copy materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production. Such an order to compel production shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection and copying commanded.
- (3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it
  - falls to allow reasonable time for compliance,
- (ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that,

subject to the provisions of clause (c)(3)(B)(fil) of this rule, such a person may in order to attend trial be commanded to travel from any such place within the state in which the trial is held, or

- (iii) requires disclosure of privileged or other protected matter and no exception or waiver applies, or
  - (iv) subjects a person to undue burden.
    - (B) If a subpoena

 requires disclosure of a trade secret or other confidential research, development, or commercial information, or

(ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or

(iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject to or affected by the subpoena, quash or modify the subpoena, or, if the party in whose behalf the subpoena is Issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

- (1) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.
- (2) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.



TO: Ruder Finn, Inc., 301 East 57th St., New York, NY 10022.

### **EXHIBIT A**

- 1. "AstraZeneca" shall mean Zeneca, Inc., AstraZeneca US, AstraZeneca Pharmaceuticals, LP, AstraZeneca, PLC, AstraZeneca Pharmaceuticals, LP (collectively "AstraZeneca") and its predecessors, subsidiaries, parent organizations, branches, departments, agents, divisions and/or affiliates, including but not limited to, any other organization in which it has management or controlling interest(s), together with all present and former directors, officers, employees, agents and representatives of AstraZeneca, and any person acting or purporting to act on its behalf.
- 2. "You" means Ruder Finn, Inc. as well as its predecessors and successors and its employees, officers, directors, agents, attorneys, affiliates or any person acting on your behalf.
- 3. The term "document" includes, without limitation, the originals of all writings of every kind, including but not limited to letters, telegrams, memoranda, reports, studies, legal pleadings, speeches, calendars, diary entries, travel records and vouchers, promotional materials, pamphlets, handwritten notes, drafts, lists, directives, reports, tabulations, minutes and records of meetings, and telephone records, which are now or formerly were in the actual or constructive possession and control of you, your officers, directors, employees, attorneys or other agents. The term "document" further includes data processing and computer printouts, tapes, disks, and data stored in computers or data processing equipment, together with programs and program documentation necessary to retrieve, read and utilize such data, and all other mechanical or electronic means of storing or recording data, as well as tape, film or cassette sound and/or visual recordings, and reproductions or film impressions of any of the aforementioned writings. The term "document" also includes copies of all documents which are not identical duplicates of the originals, and copies

of documents if the originals of documents are not in the possession, custody or control of you, your officers, directors, employees, attorneys or other agents. Alteration of documents includes, without limitation, any modification, censorship, redaction, addition to or changing, which obscures, removes, amends, changes or obliterates any part of the original language, information, or meaning.

- 4. The term "communication" shall mean any act, action, oral speech, written correspondence, contact, expression of words, thoughts, or ideas or transmission of exchange of data or other information to another person, whether orally, person-to-person, in a group, by telephone, letter, personal delivery, telex, facsimile, or any other process, electric, electronic or otherwise. All such communications in writing shall include, without limitation, printed, typed, handwritten, electronic, or other readable documents.
- 5. Unless otherwise specifically stated herein, the period covered by each of these requests extends from January 1, 1991 to the date of your response to these discovery requests.
- 6. "Relating to" or "related to" shall include describing, discussing, reflecting, constituting, evidencing, referring to, pertaining to, concerning, involving, memorializing, dealing with and bearing on (whether legally, factually, or otherwise).
- 7. The connectives "and/or" are to be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside of its scope, and are not to be interpreted in such a manner as to exclude any information within the scope of the document request.
- 8. All documents produced should be produced in the order in which you maintain them in the ordinary course of your business.



- 9. You should produce the original of each document requested together with all non-identical copies and drafts of that document. If the original of a document cannot be located, a copy should be produced in lieu thereof, and should be eligible and bound or stapled in the same manner as the original.
- 10. Documents not otherwise responsive to these requests should be produced if such documents mention, discuss, refer to or explain one or more documents that are called for by these document requests or if such documents are attached to documents called for by these document requests and constitute routing slips, transmittal memoranda or letters, comments, evaluations or similar materials.
  - 11. Documents attached to each other should not be separated.
- 12. "AstraZeneca drugs" means Atacand, Nexium, Entocort, Accolate, Armidex, Casodex, Diprivan, Nolvadex, Prilosec, Pulmicort, Rhinocort, Seroquel, Toprol, Zestril, Zomig, and Zoladex and any other drugs manufactured or marketed by AstraZeneca

- All contracts or other documents relating to any agreement by you to perform services for or to be retained by AstraZeneca.
- 2. All documents reflecting any detail of the work you performed on behalf of or related to AstraZeneca, including but not limited to advertising, the preparation of brochures and the preparation of other marketing materials.
- 3. All documents related to any services of market development, brand marketing, opinion leader marketing/database management, stakeholder communications, corporate reputation relations, change management and regulatory relations counseling on behalf of AstraZeneca.



- 4. All records, diaries, calendars and invoices, relating or referring to the work performed by you on behalf of or related to AstraZeneca.
- 5. All documents prepared by you or within your control or possession concerning, mentioning or relating to AstraZeneca.
- 6. All notes prepared, drafted or otherwise used by you relating to AstraZeneca and the services you provided to AstraZeneca.
- 7. All documents not otherwise produced that concern, refer or relate to marketing, advertising or public relations work that you performed on behalf of AstraZeneca.
- 8. All documents received by you from AstraZeneca regarding pharmaceutical pricing, marketing or distribution.
- 9. All documents concerning, relating to or referring to your policy for the generation, location, retention and destruction of your documents or files.
- 10. All current and historical organizational charts for you and all of your departments.
- 11. All documents sufficient to identify the databases maintained by you and the information they contain.